NCT02546609 - The Effect Of NS-0200 Versus Placebo On Hepatic Fat Content In Patients With Non Alcoholic Fatty Liver Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 19, 2015

Primary Completion Date

November 30, 2016

Study Completion Date

January 31, 2017

Conditions

NAFLD

Interventions

DRUG

Leu-Met-Sil 0.5

NS-0200 low dose

DRUG

Leu-Met-Sil 1.0

NS-200 high dose

DRUG

Placebo

Trial Locations (13)

Virginia Commonwealth University, Richmond

University of North Carolina Chapel Hill, Chapel Hill

GI Specialists of Georgia, Marietta

Atlanta Gastroenterology Associates, Atlanta

Premier Clinical Research, Clarksville

Quality Medical Research, Nashville

Gastro One, Germantown

Sterling Research, Cincinnati

Indiana University, Indianapolis

Northwestern University, Chicago

Rocky Mountain Research, Wheat Ridge

Catalina Research Institute, Chino

University of California San Diego, San Diego